A phase II trial of hepatic ablation of metastases to modulate and enhance immunotherapy response in non-small cell lung cancer (HAMMER-NSCLC)

Authors

Institutions

Publication Details

Journal
BMC Cancer
Published
2025-09-02
DOI
https://doi.org/10.1186/s12885-025-14779-5
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A phase II trial of hepatic ablation of metastases to modulate and enhance immunotherapy response in non-small cell lung cancer (HAMMER-NSCLC)

Adam J. Schoenfeld, Christopher H. Crane, Melissa Zinovoy, Matthew Joseph Bott et al.
BMC Cancer
Cancer Immunotherapy and Biomarkers
article

A phase II trial of hepatic ablation of metastases to modulate and enhance immunotherapy response in non-small cell lung cancer (HAMMER-NSCLC)

Adam J. Schoenfeld, Christopher H. Crane, Melissa Zinovoy, Matthew Joseph Bott, Dennis M. Sopka, D.A. Roth O'Brien, Mithat Gönen, Marsha Reyngold, Paul Bernard Romesser, Daniel Richard Gomez, Matthew T. McMillan, John Cuaron, Adeel Kaiser, Vonetta M. Williams
article en

Abstract

No abstract available for this paper.
BMC CancerVol. 25(1)
Lehigh Valley Hospital-Pocono (US), Memorial Sloan Kettering Cancer Center (US), Lehigh Valley Health Network (US)
Openalex Percentile: Top 68%
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.